Section 3 of 6
Product information and disease description
273 evidence topics · 114 sources
Product description
Phase of product development
Regulatory status: Under review; rolling BLA initiated November 2025, completion anticipated by March 2027
Launch
No evidence found.
BLA completion expected in the fourth quarter of 2026 for CIS-containing disease, May 2026, superseded in November 2026
BLA completion expected in 2026, November 2025, superseded in May 2026
Investigational status
Development phase: phase 3 trial supporting the BLA
FDA Fast Track and Breakthrough Therapy designations
Breakthrough Therapy designation for the combination with pembrolizumab
Second BLA planned for intermediate-risk and high-grade Ta disease
Japan: filing planned after the U.S. submission is complete
China: phase 2 study sponsored by the licensee
Product information
Generic, brand name and therapeutic class of product
Manufacturer: CG Oncology
Development code and registry intervention names
| Registry field | Quoted record |
|---|---|
| Intervention name | “Cretostimogene Grenadenorepvec” |
| Other name | “CG0070” |
| Intervention description | “Engineered Oncolytic Adenovirus” |
| Co-administered agent | “n-dodecyl-B-D-maltoside” |
| Co-administered agent description | “Transduction-enhancing agent” |
Therapeutic class as described in the pivotal publication and by the company
Brand name
No evidence found.
Dosage forms and strengths
Viral particle dose per instillation: two reported volumes
Frozen supply of cretostimogene and DDM
Vial presentation and closed-system transfer
Transduction-enhancing agent given before cretostimogene: 5% DDM
Commercial vial strength, fill volume, and storage conditions
No evidence found.
Average sales price and wholesale acquisition cost
Not applicable.
American hospital formulary service (AHFS), or other drug classification
Registry intervention class in the pivotal trial
AHFS classification
No evidence found.
Indication
Indication sought in the initial BLA after FDA feedback
Initial BLA indication limited to CIS-containing disease, November 2025, superseded in November 2026
Populations of the Breakthrough Therapy designations
Definition of BCG failure in the pivotal trial
Pharmacology
Mechanism of action
Oncolytic immunotherapy with dual mechanisms of action
“Cretostimogene grenadenorepvec (hereafter, cretostimogene) is an oncolytic immunotherapy with dual mechanisms of action” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“it replicates in and lyses cancer cells with retinoblastoma-E2F pathway alterations and amplifies the immune response” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Serotype-5 adenovirus designed for selective replication in cells with retinoblastoma pathway alterations
Cell entry through coxsackievirus and adenovirus receptors
Tumor selectivity and the GM-CSF transgene as described by the manufacturer
Functions attributed to the elements of the construct
Direct lysis combined with immune-mediated cell death
Pharmacodynamics
Viral replication and GM-CSF expression in urine during induction, BOND-003 Cohort C
“Levels peak immediately after instillation” (opens the source at this quote in a new tab)
“Sustained local dosing” (opens the source at this quote in a new tab)
“Drop to BLOD within a week” (opens the source at this quote in a new tab)
“Effective payload delivery” (opens the source at this quote in a new tab)
Replication and transgene expression during maintenance dosing, BOND-003 Cohort C
Adenovirus serotype 5 antibodies and antibody response over time, BOND-003 Cohort C
Urinary cytokine profiling as a measure of the local immune response, BOND-003 Cohort C
Magnitude and direction of the urinary cytokine changes during induction
GM-CSF transgene expression and replication in the phase 1 study
“High levels of granulocyte-monocyte colony-stimulating factor were detected in urine after administration in all patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Virus replication was suggested based on an increase in urine CG0070 genomes between days 2 and 5 in 58.3% of tested patients (7 of 12).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Granulocyte-monocyte colony-stimulating factor transgene expression and CG0070 replication were also suggested.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Retinoblastoma phosphorylation status and response in the phase 1 study
“A subset of 18 patients was assessed for retinoblastoma phosphorylation status.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In an exploratory, retrospective assessment patients with borderline or high retinoblastoma phosphorylation who received the multidose schedules had an 81.8% complete response rate (9 of 11).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Urinary tumor DNA minimal residual disease in BOND-003 and CORE-001
Pretreatment PD-L1 expression and response in muscle-invasive disease, CORE-002
Pharmacokinetics
Local persistence in the bladder and absence of systemic exposure, BOND-003 Cohort C
Serum measurements with repeat dosing, BOND-003 Cohort C
Urine measurement of the drug and the transgene in the phase 1 study
Urinary replication and clearance in high-risk BCG-naive disease, CORE-008 Cohort A
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
Not applicable.
Special populations
Performance status and cystectomy eligibility in the pivotal trial population
Older participants in BOND-003 Cohort C
Precautions for household contacts and sexual activity after each instillation
Biosafety handling in the clinic
Use in pregnancy and lactation, in children, and in renal or hepatic impairment
No evidence found.
Drug/Drug, drug/disease interactions
Effects of other drugs on Cretostimogene grenadenorepvec
Transduction-enhancing excipient given before each instillation
Combination with systemic pembrolizumab in CORE-001
Concomitant anticancer therapy excluded in the pivotal trial
Supportive medication before or after instillation
Effects of Cretostimogene grenadenorepvec on other drugs
No evidence found.
Dosing and administration
Dosage
BOND-003 induction, second induction, and maintenance schedule
“Patients received intravesical cretostimogene (1 × 1012 viral particles per 0·8 mL per week) as 6-week induction followed by maintenance; re-induction was permitted for persistent disease at 3 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Treatment duration in BOND-003 Cohort C and its extension
Expanded access program schedule
Dose modification
No evidence found.
Administration
Intravesical catheter instillation after DDM pretreatment, without anesthesia
Optimized two-step instillation, dwell times, and staff
Preparation, biosafety handling, and premedication
Access and distribution
Expanded access program for BCG-unresponsive NMIBC
Manufacturing, storage, and distribution through third parties
Development and commercialization rights outside the United States
Co-prescribed/Concomitant therapies
Intravesical n-dodecyl-β-D-maltoside pretreatment before each instillation
Transduction-enhancing agent listed as a study intervention in BOND-003
Original five-step and optimized two-step instillation processes
Dwell times of the pretreatment agent and cretostimogene
| Instillation step | Duration |
|---|---|
| DDM | “~15 minutes” |
| Cretostimogene | “~45 to 60 minutes” |
Combination with pembrolizumab and gemcitabine under study
Prior and concurrent anticancer therapy excluded from BOND-003
Effect of Cretostimogene grenadenorepvec on quality measures
Quality measure for intravesical BCG in newly diagnosed non-muscle-invasive bladder cancer
| Field | Quoted record |
|---|---|
| Title | “Intravesical Bacillus-Calmette-Guerin for Non-Muscle Invasive Bladder Cancer” |
| MIPS Quality ID | “481” |
| Measure steward | “Oregon Urology” |
| Description | “Percentage of patients initially diagnosed with non-muscle invasive bladder cancer and who received intravesical Bacillus-Calmette-Guerin (BCG) within 6 months of bladder cancer staging” |
| Measure type | “Process” |
| Denominator exclusion | “Patients who undergo cystectomy, chemotherapy or radiation within 6 months of Bladder Cancer Staging” |
| Denominator exception | “Unavailability of BCG within 6 months after Bladder Cancer Staging” |
Product-specific effect on quality measures
No evidence found.
Product comparison
Company cross-trial comparison with approved agents in CIS-containing BCG-unresponsive disease
| Feature | Cretostimogene | TAR-200 | N-803 + BCG | Nadofaragene | Pembrolizumab |
|---|---|---|---|---|---|
| Mechanism | “Oncolytic Immunotherapy” | “Gemcitabine via In-Dwelling Device” | “IL-15 Superagonist + BCG combo” | “Gene Therapy Secreting IFN” | “Checkpoint Inhibitor” |
| Route of administration | “Intravesical” | “Transurethral Procedure” | “Intravesical” | “Intravesical” | “Intravenous” |
| CR at any time | “75.5% (83/110)” | “82.4% (70/83)” | “62.3% (48/77)” | “51.0% (50/98)” | “40.6% (39/96)” |
| CR at 12 months | “46.4% (51/110)” | “K-M: 45.9% (39/83)” | “36.4% (28/77)” | “24.3% (25/103)” | “18.8% (18/96)” |
| CR at 24 months | “41.8% (46/110)” | “Not Reported” | “24.7% (19/77)” | “19.4% (20/103)” | “9.4% (9/96)” |
| Grade 3 or higher treatment-related adverse events | “0%” | “13%” | “Not reported; 16% SAE” | “4%” | “13%” |
| Treatment-related discontinuation | “0%” | “3.5%” | “7%” | “3%” | “11%” |
Guideline table of bladder-sparing options for carcinoma in situ with or without papillary disease
| Compound | Study design | n | Follow-up (months) | CR at 3 months (%) | CR at 6 months (%) | CR at 12 months (%) | Adverse events |
|---|---|---|---|---|---|---|---|
| Nadofaragene firadenovec | “Phase III Cis Cohort” | “103” | “19.7” | “53.4” | “40.8” | “24.3” | “G3 4%” |
| Cretostimogene grenadenorepvec (CG0070) | “Phase II” | “45” | Not reported | Not reported | “58 CIS”; “50 CIS+P” | Not reported | “G1-2 82.5% G ≥ 3 4.5%” |
| Nogapendekin alfa inbakicept plus BCG | “Phase II/III QUILT 3032 CA” | “82” | “23.9” | “55.0” | “56.0” | “45.0” | “G1-2 86% G ≥ 3 23%” |
| TAR-200 | “Phase II b SunRISe-1 C2” | “81” | “20.2” | “78.8” | “58.8” | “45.9” | “Any G 83.5% G ≥ 3 12.9%” |
| Pembrolizumab | “Phase II Cohort A KEYNOTE-057” | “96” | “36.4” | “41.0” | Not reported | “18.7” | “G1-2 53.0% G ≥ 3 13%” |
Re-induction at 3 months as a difference in trial design
“Recently, a CR rate of 75% was reported for the investigational agent cretostimogene grenadenorepvec in patients with BCG-unresponsive CIS, although this CR rate included patients with persistent disease who underwent repeat induction treatment, which was not permitted in SunRISe-1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Acknowledging the limitations of indirect cross-study comparisons, TAR-200 was associated with a higher CR rate than both conventional gemcitabine instillation and FDA-approved novel agents (pembrolizumab, nadofaragene firadenovec, and NAI + BCG), ranging from 41% to 62%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Nadofaragene firadenovec: indication, dosing, and efficacy in prescribing information
| Feature | Quoted label text |
|---|---|
| Indication | “(BCG)-unresponsive non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors” |
| Dosing interval | “instilled once every three (3) months into the bladder via a urinary catheter” |
| Premedication | “Premedication with an anticholinergic is recommended before each instillation of ADSTILADRIN.” |
| Complete response rate | “51%” |
| Median duration of response, months (range) | “9.7 (3, 52+)” |
| Responders with duration of 12 months or longer | “46%” |
Nogapendekin alfa inbakicept: indication, dosing, and efficacy in prescribing information
| Feature | Quoted label text |
|---|---|
| Indication | “ANKTIVA, in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC).” |
| Induction | “400 mcg administered intravesically with BCG once a week for 6 weeks.” |
| Maintenance | “400 mcg administered intravesically with BCG once a week for 3 weeks at months 4, 7, 10, 13 and 19.” |
| Bladder retention | “ANKTIVA in combination with BCG admixture should be retained in the bladder for 2 hours and then voided.” |
| Complete response rate (95% CI) | “62% (51, 73)” |
| Responders with duration of 12 months or longer | “58% (28)” |
| Responders with duration of 24 months or longer | “40% (19)” |
Gemcitabine intravesical system: indication, dosing, and efficacy in prescribing information
| Feature | Quoted label text |
|---|---|
| Indication | “INLEXZO is indicated for the treatment of adult patients with Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors.” |
| Dosing | “Insert INLEXZO (225 mg of gemcitabine) into the bladder once every 3 weeks up to 6 months (8 doses), followed by once every 12 weeks (6 doses).” |
| Insertion | “Insert into the bladder using the co-packaged urinary catheter and stylet only.” |
| Complete response rate (95% CI) | “82% (72, 90)” |
| Responders with duration of 12 months or longer | “51% (35)” |
Pembrolizumab: indication, dosing, and efficacy in prescribing information
| Feature | Quoted label text |
|---|---|
| Indication | “KEYTRUDA, as a single agent, is indicated for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.” |
| Dosing | “200 mg every 3 weeks”; “400 mg every 6 weeks” |
| Duration of therapy | “Until persistent or recurrent high-risk NMIBC, disease progression, unacceptable toxicity, or up to 24 months” |
| Administration | “Administer KEYTRUDA as a 30-minute intravenous infusion.” |
| Complete response rate (95% CI) | “41% (31, 51)” |
| Median duration of response, months (range) | “16.2 (0.0+, 30.4+)” |
| Responders with duration of 12 months or longer | “46% (18)” |
Place of product in therapy
Disease description
Definition and etiology
Definition of non-muscle-invasive bladder cancer
Definition and clinical classification of carcinoma in situ
High-risk and very high-risk NMIBC: EAU prognostic factor risk groups
Definition of BCG-unresponsive disease: FDA guidance
Categories of BCG failure: EAU definitions
BCG-exposed disease: high-grade recurrence outside the BCG-unresponsive criteria
International Bladder Cancer Group classification of BCG failures
“Table 5 summarizes our classification of BCG failures, dividing them into the following four types: BCG refractory, BCG relapsing, BCG intolerant, and BCG unresponsive.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Persistent high-grade disease at 6 months despite adequate BCG” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The term BCG unresponsive, which essentially includes BCG refractory and BCG relapsing (within 6 months of last BCG exposure), is meant to denote a subgroup of patients at highest risk of recurrence and progression for whom additional BCG therapy is not a feasible option.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For clinical trials, adequate BCG therapy is when a patient has received at least five of six induction instillations and at least one maintenance (two of three instillations) in a 6-month period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Origin of the term BCG-unresponsive: 2015 Genitourinary Cancers Symposium task force
“identifies those patients with high grade (HG) NMIBC who have been treated with adequate BCG (see below) and are unlikely to benefit from and should not receive further intravesical BCG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Have received at least 2 courses of intravesical BCG – defined as at least 5 of 6 induction instillations of BCG and at least 2 of 3 instillations of maintenance BCG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Exception: those who have T1HG disease at first evaluation following induction BCG alone (at least 5 of 6 doses) would qualify.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We also recommend including CIS of the prostatic urethra within the definition of BCG unresponsive” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Data-driven definition of BCG-unresponsive disease
“Those with CIS recurrence at 6–12 months did not differ from those recurring within 6 months (HR = 0.88, p = 0.71).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients who fail two courses of BCG with either persistent or recurrent multifocal papillary disease within 6 months or CIS within 12 months of their prior BCG should be considered BCG unresponsive.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Etiology of bladder cancer: tobacco smoking
Etiology of bladder cancer: occupational, environmental, and treatment-related exposures
Etiology of bladder cancer: genetic factors
Epidemiology
Incidence of BCG-unresponsive high-risk non-muscle-invasive bladder cancer
Bladder cancer new cases in the United States, 2026 estimate
Bladder cancer incidence rate, lifetime risk, and age at diagnosis
Share of bladder cancer diagnosed as non-muscle-invasive disease
Population funnel from bladder cancer to BCG-unresponsive high-risk NMIBC, SEER and SEER-Medicare inputs
Population funnel assumptions in the ICER review: NMIBC stage mix and BCG non-response
BCG-unresponsive share among recurrences after BCG, US electronic health record and claims cohort
“The study included 26 876 patients with NMIBC (median [IQR] age at BCG initiation, 73 [65-77] years; 79.5% male), including 9639 patients with carcinoma in situ” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of 5271 patients with carcinoma in situ–containing tumors and sufficient follow-up, 3134 (59.3%) experienced recurrence within 24 months, of whom 2604 (83.1%) were BCG exposed and 530 (16.9%) were BCG unresponsive.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
BCG-unresponsive share among classifiable BCG-treated high-grade NMIBC, single-center cohort
“We conducted a retrospective cohort study for adults with histologically confirmed high-grade NMIBC treated with intravesical BCG at Moffitt Cancer Center between 1988 and 2024.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of 1076 NMIBC patients treated with BCG, 470 were classifiable: 245 (52.1%) were BCG-E, of whom 173 (70.6%) were resistant and 72 (29.4%) experienced delayed relapse, and 225 (47.9%) were BCG-UR.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of BCG-unresponsive high-risk non-muscle-invasive bladder cancer
Bladder cancer prevalence in the United States
Prevalent population eligible for treatment of BCG-unresponsive high-risk NMIBC, ICER estimate
Eligible population per 1 million health plan members, budget impact model estimate
Limits of classifying BCG-unresponsive disease in real-world data
“As a result, a substantial proportion of patients cannot be classified under existing criteria because the exposure-based and time-dependent conditions required by regulatory definitions are not met in routine practice.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Maintenance BCG is infrequently delivered, surveillance intervals vary widely, early radical cystectomy is limited by system-level and institutional factors, and key tumour-level variables required for classification are often missing in large-scale datasets.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Natural history, survival, and mortality
Bladder cancer mortality in the United States
Five-year relative survival overall and for in situ disease
Recurrence, progression, and bladder cancer mortality after high-grade NMIBC, SEER-Medicare
“Of 7,410 subjects, 2,897 (39.1%) experienced a recurrence without progression, 2,449 (33.0%) experienced disease progression, of whom 981 succumbed to bladder cancer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Using competing-risks regression analysis, we found the 10-year recurrence, progression, and bladder cancer-related mortality rates to be 74.3%, 33.3%, and 12.3%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nearly three-fourths of patients diagnosed with high-risk bladder cancer will recur, progress, or die within ten years of their diagnosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Probability of progression at five years by prognostic risk group
“From the multivariable analyses, tumor stage, WHO 1973/2004-2016 grade, concomitant carcinoma in situ, number of tumors, tumor size, and age were used to form four risk groups for which the probability of progression at 5 yr varied from <1% to >40%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Risk of progression and metastasis after BCG failure
Survival with BCG-unresponsive high-risk NMIBC, SEER-Medicare model input
BCG-refractory compared with BCG-relapsing disease, prospective cohort
“Seventeen patients were classified as BCG refractory and 15 patients defined BCG relapsing.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Progression-free survival time was 18 months for BCG-refractory vs. 52 months for BCG-relapsing patients (P = 0.001). Of the 17 BCG-refractory patients, 8 (47%) have died vs. 3 (20%) of the 15 BCG-relapsing patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Progression and disease-specific death after T1 recurrence following BCG
“In the historical cohort the 85 patients with documented T1 recurrence were initially treated with repeat transurethral resection and intravesical bacillus Calmette-Guerin.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At 5 years after T1 recurrence, the cumulative incidence of progression to T2 disease was 71% (95% CI 61%, 81%) and the cumulative incidence of death from disease was 48% (95% CI 39%, 60%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In this cohort 65 of the 129 patients with recurrent T1 underwent immediate radical cystectomy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At 5 years after T1 recurrence, the cumulative incidence of progression to muscle invasive disease was 28% (95% CI 20%, 38%) and the cumulative incidence of death from disease was 31% (95% CI 22%, 42%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Recurrence and progression with bladder-sparing therapy in BCG-unresponsive NMIBC, international multicenter cohort
“Among 578 patients, 28% underwent upfront RC and 72% received BST. The median (interquartile range) follow‐up was 50 (20–69) months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no statistically significant differences in metastasis‐free survival, cancer‐specific survival, or overall survival between treatment groups. In the BST group, high‐grade recurrence rates were 37% and 52% at 12 and 24 months and progression to MIBC was observed in 7% and 13% at 12 and 24 months, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cancer‐specific survival (CSS) is >80% after RC is performed for NMIBC” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term survival in BCG-unresponsive NMIBC, single-center registry
“In total, 114 patients with a median follow-up of 71.2 mo (interquartile range: 32.6–132.2) were analyzed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no significant differences in OS (hazard ratio [HR]: 1.40, 95% confidence interval [CI]: 0.68–2.89, p = 0.4) or CSS (HR: 0.88, 95% CI: 0.22–3.55, p = 0.9) between patients undergoing early RC” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At 60 mo, BST patients had a high-grade recurrence-free rate, muscle-invasive disease/metastasis progression-free rate, and avoidance of RC rate of 37%, 83%, and 58%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Recurrence, progression, and cystectomy after BCG, US electronic health record and claims cohort
Outcomes in BCG-exposed high-grade NMIBC not meeting the unresponsive definition, single-center cohort
“In the BCG-E group, 50.2% experienced recurrence and 15.5% experienced progression; median recurrence-free survival (RFS) was 27.2 mo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The 5-yr survival rate estimates were 32.25% for RFS, 79.3% for progression-free survival (PFS), 84.5% for metastasis-free survival (MFS), and 65.0% for overall survival (OS).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Clinical outcomes within 12 months of high-grade recurrence after BCG, prospective CISTO cohort
“Of 570 participants (mean age 71.4 years; 21% female), 371 selected BST and 199 selected RC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cancer-specific survival was 99% for BST versus 96% for RC (wRR, 0.99; 95% CI, 0.97 to 1.01). RC was associated with a higher risk of adverse events and serious adverse events, including a 90-day mortality rate of 2.5%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Within 12 months, 27 (8.1%) participants in the BST arm underwent an eventual RC, including 21 (6.3%) for recurrent high-grade NMIBC and four (1.2%) for progression to MIBC” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because 22% of patients undergoing RC had pathology demonstrating MIBC, 12-month progression-free survival (PFS) was lower for RC (73% v 92% for BST; wRR, 0.81 [95% CI, 0.74 to 0.88];” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Survival after radical cystectomy for BCG failure
“We retrospectively analyzed the records of 117 patients who underwent radical cystectomy for recurrent nonmuscle invasive bladder cancer at our institution from 1990 to 2012.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Five-year overall and cancer specific survival was similar in groups 1 and 2 at 80% and 85%, respectively, at approximately equivalent followups.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among 93 patients, 64 (68.8%) had clinical NMIBC, and 29 (31.2%) showed clinical progression to muscle-invasive bladder cancer (MIBC) prior to RC.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with pNMIBC had significantly better 5-year CSS (95.5%) and OS (77.6%) compared to those with clinical (CSS 70.4%, OS 50.2%) or subclinical progression (CSS 64.1%, OS 43.8%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Salvage radical cystectomy compared with BCG rechallenge in BCG-unresponsive NMIBC, Japanese multicenter databases
“In the adjusted BCG-unresponsive NMIBC cohort, no differences in MFS or OS were detected (p = 0.76 and p = 0.35, respectively), although long-term survival outcomes appeared better in the salvage RC group than in the BCG rechallenge group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Early mortality after radical cystectomy
Early mortality after radical cystectomy for muscle-invasive disease, National Cancer Database
Pathophysiology
Urothelial carcinogen exposure and detoxification
Field defect and multifocal disease
Molecular drivers and transcriptomic classes of NMIBC
“Activating mutations in FGFR3 and PIK3CA and chromosome 9 deletions have been identified as early disease drivers” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Transcriptomic analysis identifies four classes (1, 2a, 2b and 3) reflecting tumor biology and disease aggressiveness.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“High chromosomal instability, p53-pathway disruption and APOBEC-related mutations are significantly associated with transcriptomic class 2a and poor outcome.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“RNA-derived immune cell infiltration is associated with chromosomally unstable tumors and enriched in class 2b.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Molecular subtypes associated with response and failure after BCG
“Here we conducted molecular profiling of 132 patients with BCG-naïve HR-NMIBC and 44 patients with recurrences after BCG (34 matched), which uncovered three distinct BCG response subtypes (BRS1–3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with BRS3 tumors had reduced recurrence and progression-free survival compared to BRS1/2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“BRS3 tumors expressed high EMT-basal markers and had an immunosuppresive profile, which was confirmed with spatial proteomics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“BRS3-predicted tumors were enriched in post-BCG 28/44 (64%) recurrences vs pre-BCG tumors 82/283 (28%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“From the 34 matched tumors, 26/34 patients had BRS1/ 2 tumors pre-BCG of which 14/26 tumors switched to BRS3 post-BCG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adaptive immune resistance as a mechanism of BCG failure
“The final cohort contained 63 pretreatment NMIBC cases, including 31 BCG responders and 32 BCG nonresponders.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Baseline PD-L1 expression (22C3 and SP-142) was observed in 25% to 28% of nonresponders and 0% to 4% of responders (P < 0.01).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“PD-L1+ cells in BCG nonresponders colocalized with CD8+ T cells.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“One mechanism of BCG failure may be adaptive immune resistance.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Biological differences between papillary-only and CIS-containing disease after BCG
Diagnosis
Cystoscopy and histological confirmation
Transurethral resection and bladder and prostatic urethral biopsies
Imaging and evaluation of the upper urinary tract
Urinary molecular markers after BCG
Detection of recurrence during follow-up of high-risk disease
Establishing BCG-unresponsive status: documentation of prior BCG
“Type of BCG schedule administered before failure (including induction and maintenance: instillations per course, schedule of instillations and duration)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The timing of recurrence and type of BCG schedule administered before failure should also be documented.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Characterization of disease extent in BCG-unresponsive trials
Clinical presentation - signs and symptoms
Urinary bleeding: visible or nonvisible haematuria
Lower urinary tract symptoms: irritative voiding symptoms with carcinoma in situ
Physical signs: no findings on examination
Cystoscopic signs: flat reddish or nonvisible carcinoma in situ
Laboratory signs: malignant urine cytology with normal-looking mucosa
Extravesical disease: upper urinary tract and prostatic urethral involvement
Long-term morbidity
Burden of repeated recurrence and surveillance with the bladder in place
Lifestyle effects of radical cystectomy and patient reluctance
“but radical surgery comes with substantial risk” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“and dramatic lifestyle changes. Further, many patients are unwilling to accept major surgery until all other possibilities are exhausted.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Complications within 90 days of radical cystectomy
“Sixty-four percent (735/1142) of patients experienced a complication within 90 d of surgery.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, the highest grade of complication was grade 0 in 36% (n=407), grade 1-2 in 51% (n=582), and grade 3-5 in 13% (n=153).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Gastrointestinal complications were most common (29%), followed by infectious complications (25%) and wound-related complications (15%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Adverse events and readmission after radical cystectomy compared with bladder-sparing therapy, CISTO cohort
“Participants who selected RC were significantly more likely to experience AEs (62% v 38% for BST; wRR, 1.61 [95% CI, 1.35 to 1.91],” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“including gastrointestinal, infectious, wound, thromboembolic, and bleeding complications.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among participants who selected RC, 15 (8.0%) experienced prolonged hospitalization after their RC, 57 (30%) were readmitted within 90 days, and five (2.5%) died within 90 days” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“while BST was associated with better bowel and sexual health.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term complications of conduit urinary diversion
“There were 643 (60.8%) patients with 1,453 complications directly attributable to the urinary diversion performed with a mean of 2.3 complications per patient.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Bowel complications were the most common, occurring in 215 patients (20.3%), followed by renal complications in 213 (20.2%), infectious complications in 174 (16.5%), stomal complications in 163 (15.4%) and urolithiasis in 162 (15.3%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Long-term followup of these patients is necessary to closely monitor for potential complications from the urinary diversion that can occur decades later.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Kidney function decline after cystectomy with urinary diversion
“Among 563 patients who underwent cystectomy with urinary diversion, a NB was used for 72 (12.8%) individuals.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Both NB and IC patients had decreased kidney function over time, with mean GFR losses at 5 years of 17% and 14% of baseline values, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Late complications after robot-assisted radical cystectomy with intracorporeal urinary diversion
“The mean follow-up was 30 ± 22 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The stenosis rate of uretero-ileal anastomosis was 14%, while a reduction in eGFR (≥ 20%) was observed in about half of the cases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“UTIs occurred in 37% of the patients, especially in the first 12 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Burden of BCG-unresponsive high-risk non-muscle-invasive bladder cancer
Humanistic burden and health-related quality of life
Radical cystectomy versus bladder-sparing therapy: 12-month patient-reported outcomes in recurrent high-grade NMIBC after BCG
“Eligible adults were candidates for both RC or BST, had previous induction Bacillus Calmette-Guérin (BCG), and received their last treatment within 12 months. The primary outcome was the EORTC-QLQ-C30 physical function scale at 12 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of 570 participants (mean age 71.4 years; 21% female), 371 selected BST and 199 selected RC. Physical function was significantly worse in the RC arm at 3 months; by 9 months, there was no difference between arms, and at 12 months, physical function did not differ (ATE, 0.9; 95% CI, –0.6 to 2.4; P = .22). RC was associated with better emotional function, generic health-related QOL, and financial burden, and lower depression and anxiety, while BST was associated with better bowel and sexual health.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At 12 months, the primary outcome of EORTC QLQ-C30 physical function did not differ between the BST arm and the RC arm (mean 85.4 [SD, 17.7] v 86.2 [17.6], respectively; ATE, 0.9 [95% CI, –0.6 to 2.4]; P = .22; Fig 2, Data Supplement, Table S10).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Emotional function, cognitive function, global health, anxiety, and depression were significantly better in the RC arm 12 months after enrollment (Fig 2). There were no significant differences between treatment arms in role function and social function.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants in the RC arm had significantly worse 12-month bowel and sexual summary scores than those in the BST arm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“EORTC QLQ-C30 physical and role function were significantly worse in the RC arm at 3 months compared with the BST arm, but no significant treatment effects were observed by 9 months, including for physical function among participants age 75 years and older. Emotional function and anxiety were better in the RC arm at all follow-up time points. Urinary and bowel health were significantly worse in the RC arm at 3 months. By 12 months, there were no significant differences between the two treatments with respect to urinary health, but bowel health remained worse in the RC arm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-state utilities elicited for BCG-unresponsive NMIBC and progression to cystectomy
“The purpose of this study was to elicit the general public’s perspective on quality of life, measured as utility scores associated with treatment for Bacillus Calmette-Guerin (BCG)-unresponsive NMIBC and disease progression, for supporting economic evaluation of newly developed treatments for NMIBC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Time trade-off (TTO) interviews were conducted with members of the UK general public.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In total, 202 members of the general public participated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean utilities were 0.781 for No High-Grade Recurrence, 0.586 for High-Grade Recurrence, 0.572 for > 1-Year Post-cystectomy and 0.283 for metastatic disease. The First Year Post-cystectomy path health state had a mean utility of 0.288. Pairwise comparisons found statistically significant differences between utilities (p < 0.001), except between High-Grade Recurrence and > 1-Year Post-cystectomy (p = 0.524).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Utility values used in a U.S. cost-effectiveness model of BCG-unresponsive carcinoma in situ
“We derived quality-adjusted life years (QALYs) from literature-reported utility values for bladder cancer health states (Table 3), adjusting for the health state's utility toll and duration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Patient preferences for bladder-sparing treatment versus radical cystectomy
“Patients with self-reported NMIBC completed an online discrete-choice experiment survey evaluating their preferences for efficacy-, safety-, and administration-related treatment attributes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 206 respondents completed the survey. Reduced risks of progression to MIBC and NMIBC recurrence were the most important of the attributes evaluated, followed by, in order, chance of immune-related side effects requiring steroids, mode and frequency of administration, treatment-related fatigue, and urinary symptoms or infection. In fixed direct-elicitation questions, most patients (>70%) preferred bladder-sparing treatments over RC except when comparing repeated Bacillus Calmette-Guérin treatment to RC.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Over 25% of respondents disagreed with the statement "My doctor asked me which treatment option I prefer" when reflecting on their shared decision-making experiences.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Treatment burden of intravesical therapy: travel, caregiver support, and daily activities
“Two hundred thirty-three patients responded to the survey with median age of 70 years (range 33-88 years). Two-thirds of respondents (66%, 151/232) had received greater than 12 bladder instillations.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Sixty-one respondents (26%) felt the process of receiving bladder instillations adversely affected their ability to perform regular daily activities. Among those surveyed, 72% (168/232) reported openness to receiving in-home intravesical instillations and 54% (122/228) answered that in-home instillations would make the treatment process less disruptive to their lives.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Quality of life with frequent intravesical instillations: systematic review
“A total of 17 studies were selected, comprising 6 qualitative, 8 quantitative, and 3 mixed-methods designs, totaling 20,045 patients. Frequent instillations were associated with increased urinary symptoms (e.g., urgency and dysuria), fatigue, and emotional distress. Withdrawal rates were high (up to 90%) in intensive schedules, particularly during the first year, due to treatment burden and side effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Frequent intravesical instillations can significantly impair QoL, particularly among older patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Quality of life during cystoscopic surveillance: systematic review
“NMIBC survivors had significantly lower QoL compared to the general population, Surveillance strategies involving repeated intravesical therapies and cystoscopies have a negative impact on QoL with impaired physical function and mental health.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Surveillance is also tailored according to the risk strata. The frequency of surveillance increases with the increase in risk accordingly impacting the QoL” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“most guidelines advocate 3-month cystoscopy for 2 years, then every 6 months for 5 years and then annually (39), provided there is no recurrence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Quality of life of NMIBC survivors compared with the general population
“Non-muscle-invasive bladder cancer survivors had significantly lower QOL compared with the general population, especially in fatigue, physical and role functioning, and mental health. Repeated transurethral resections and intravesical treatments were associated with impaired physical function and mental health. Most NMIBC survivors had concerns of urinary and bowel problems and sexual function.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Patient-reported outcomes during bladder-sparing therapy in BCG-unresponsive NMIBC: N-803 plus BCG
“Both cohort A patients with carcinoma in situ with or without Ta/T1 disease and cohort B patients with high-grade Ta/T1 papillary disease who received N-803 plus BCG therapy completed the EORTC (European Organization for Research and Treatment of Cancer) Core 30 and Quality of Life NMIBC-Specific 24 questionnaires at baseline and months 6, 12, 18, and 24 on study.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“On study, mean physical function (PF) and global health (GH) scores remained relatively stable from baseline for cohorts A (n = 86) and B (n = 78).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“NMIBC-Specific 24 summary scores also remained stable on study for both cohorts.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Patient-reported outcomes during bladder-sparing therapy in BCG-unresponsive NMIBC: gemcitabine and docetaxel
“PRO assessments were performed using the validated European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and NMIBC24 questionnaires.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Sixty-three patients were included.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Urinary symptom burden, global function, and functional outcomes remained stable during treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Economic burden and healthcare resource utilization
Healthcare resource utilization and costs after BCG in high-grade NMIBC, by progression status
“Patients aged ≥ 65 years diagnosed with HG-NMIBC between 2008 and 2015 who received adequate BCG induction and were identified in the SEER-Medicare database.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of 986 patients diagnosed with HG-NMIBC who met the inclusion criteria, 257 (26.1%) progressed; the mean ages were similar between patients who did and did not progress (77.6 vs. 77.0 years). The overall population had a mean of 0.96 [standard deviation (SD): 1.18] inpatient admissions, 6.47 (11.40) hospitalization days, 1.38 (2.19) emergency department (ED) visits, and 48.03 (44.97) outpatient visits per patient-year during the study period; total annualized costs per patient post-BCG were $39,102 ($44,244).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients experiencing progression had significantly higher mean numbers of inpatient admissions [1.61 (SD 1.40) vs. 0.72 (0.99)], hospitalization days [11.77 (14.96) vs. 4.59 (9.29)], ED visits [2.34 (2.92) vs. 1.03 (1.76)], and outpatient visits [65.97 (44.72) vs. 41.63 (43.09)] per patient-year compared with patients without progression (all p < 0.05). Total mean annualized costs per patient after BCG among those who progressed [$65,668 (SD $53,943)] were more than double compared with patients who did not [$29,780 ($36,425)].” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Costs of high-risk NMIBC after BCG in the Veterans Affairs Health System, by progression status
“This retrospective cohort study identified 412 patients with high-risk NMIBC from 63 139 patients diagnosed with bladder cancer who received at least 1 dose of BCG within Department of Veterans Affairs (VA) centers across the US from January 1, 2000, to December 31, 2015.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All-cause expenditures were summarized as medians with corresponding interquartile ranges (IQRs) and adjusted to 2019 USD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Total median costs at 1 year were $29 459 (IQR, $14 991-$52 060); at 2 years, $55 267 (IQR, $28 667-$99 846); and at 5 years, $117 361 (IQR, $59 680-$211 298). Patients with progressive disease had significantly higher median 5-year costs ($232 729 [IQR, $151 321-$341 195] vs $94 879 [IQR, $52 498-$172 631]; P < .001), with outpatient care, pharmacy, and surgery-related costs contributing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Costs and resource use of radical cystectomy and trimodal therapy in the United States
“Of 1323 patients, 839 underwent RC (median age 71 years; 26.2% female), and 484 received trimodal therapy (median age 75; 26.2% female). Median [IQR] per-patient costs were $70,671 [$55,878-$106,812] for the RC cohort at 90-days follow-up and rose to $211,671 [$138,597-$346,389] by 5-years post-index. For trimodal therapy, total costs were $34,612 [$16,705-$64,263] at 90-days and increased to $274,462 [$186,337-$421,534] by 5-years. At 90-days, median overall visits (inpatient, outpatient, emergency room, or other) were 26 [16-39] for RC and 19 [12-33] for trimodal therapy; overall visits were 163 [119-218] and 186 [144-238] by 5-years, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This analysis reveals that RC costs were primarily driven by inpatient services, particularly inpatient facility costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Medicare costs of bladder cancer care by phase of care
| Phase of care | Annualized cancer-attributable medical services cost, bladder cancer (2019 US thousand dollars) |
|---|---|
| Initial (first 12 months after diagnosis) | “$25.4”View highlighted excerpt for this quote |
| Continuing | “$6.1”View highlighted excerpt for this quote |
| End of life, cancer death | “$92.2”View highlighted excerpt for this quote |
| End of life, non-cancer death | “$21.8”View highlighted excerpt for this quote |
National costs of bladder cancer care in the United States, 2015 and projected to 2030
“Cancer sites for which population changes will increase costs more than the average (39%) from 2015 through 2030 are bladder (45%), kidney (54%), leukemia (51%), melanoma (51%), Non-Hodgkin (45%), prostate (46%) and thyroid (55%) cancers (Table 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Year | National cost of bladder cancer care, Medicare Parts A, B, and D (2019 US billion dollars) |
|---|---|
| 2015 | “$8.0”View highlighted excerpt for this quote |
| 2020 | “$9.0”View highlighted excerpt for this quote |
| 2025 | “$10.2”View highlighted excerpt for this quote |
| 2030 | “$11.6”View highlighted excerpt for this quote |
Costs of high-risk NMIBC progressing after BCG: systematic review
“Non-muscle-invasive BCa (NMIBC) incurs significant costs for surveillance and treatment, with costs exceeding $200 000 after 5 yr for high-risk NMIBC patients progressing after bacillus Calmette-Guerin (BCG) treatment (including inpatient, outpatient, and physician service expenses). Muscle-invasive BCa generates substantial costs from radical cystectomy (RC) and neoadjuvant chemotherapy, averaging $30 000-40 000 from surgical costs of RC, with additional expenses in case of complications.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Per-patient and lifetime cost of bladder cancer
“Collectively, this results in bladder cancer having the highest cost of any malignancy when stratified on a per-patient basis [7]. A patient diagnosed with localized bladder cancer from the years 1998-2013 contributed to a lifetime cumulative expenditure of roughly $124,000 to Medicare, which is likely higher today given new treatment regimens and higher costs [8].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of BCG-unresponsive high-risk non-muscle-invasive bladder cancer on families
Caregiver attendance, missed work, and travel for intravesical therapy
“A travel time of >30 minutes to an intravesical treatment facility was reported by 55% (126/231) of respondents. Fifty-six percent (128/232) brought caregivers to their appointments, and 36% (82/230) missed work to receive treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Bladder cancer patients reported considerable travel distances, time requirements, and need for caregiver support when receiving intravesical therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Financial toxicity after radical cystectomy versus bladder-sparing therapy
“Financial toxicity was measured with the Comprehensive Score for Financial Toxicity (COST),” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“which includes questions about concern with covering the costs of treatment, out-of-pocket expenses, ability to work, and impact and worry about finances. COST scores range from 0 to 44, with lower scores indicating greater financial distress.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants in the BST arm reported significantly higher financial toxicity and financial difficulties 12 months after enrollment than participants in the RC arm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants in the BST and RC arms endorsed similar financial burden at enrollment. However, by 12 months, participants in the RC arm experienced lower financial difficulties and lower financial toxicity. Although RC is a morbid surgery with a high initial burden, after recovery, those patients mostly experience low health care utilization. Conversely, patients undergoing BST have several induction and maintenance treatments in the year after their recurrence coupled with quarterly surveillance cystoscopies. The financial burden of BST may increase going forward, given recent US Food and Drug Administration approvals of nadofaragene and nogapendekin for BCG-unresponsive NMIBC, which are substantially more expensive than currently available BSTs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Financial toxicity among patients with NMIBC in a diverse urban population
“Hundred patients with NMIBC were surveyed. The median age was 74 years (IQR, 66-79).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The median COST score was 23 (IQR,15-33). 61% of patients reported at least mild FT (COST score 25-14). A total of 21% reported moderate FT (COST score < 14). Black patients were more likely to experience FT than Caucasians (73% vs 37%, P < .05).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall median household income was $30,000 (IQR, $18,250-$60,750), and increasing income had a significant positive correlation with COST score (Spearman ρ = 0.502, P < .001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Financial toxicity in bladder cancer: definition and associated factors
“Financial toxicity (FT) refers to the detrimental effects of financial strain caused by a cancer diagnosis on the well-being of patients and their families.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of 629 titles identified, 19, ten, and two studies met the inclusion criteria for prostate, bladder, and kidney cancer, respectively, and were included (24 unique articles).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Factors commonly associated with FT included younger age at diagnosis, black race, low socioeconomic status, low education attainment, and rurality. FT was commonly associated with lower quality of life and nonadherence.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Indirect costs: lost productivity, retirement, and unemployment
“Lost productivity for example, contributed to 44% of total cancer care costs in a study of Italian BC patients, and 67% of costs in a recent Iranian study [11-12]. Additionally, this effect may be permanent for many as bladder cancer patients face a roughly 60% retirement rate following diagnosis and 22% unemployment rate for previously full-time workers [13].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Those who are younger, without a college degree, and are black all experience worse financial toxicity [15].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver financial strain after radical cystectomy with urinary diversion
“Financial strains, including medical costs and potential work interruptions, further complicate their role.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Financial worries were also evident, as a study involving 123 caregivers, 17% of whom were attending to bladder cancer patients with urostomy, revealed heightened economic concerns. The findings suggested pronounced financial strain among caregivers with young children (34%) and those who were older (mean age=56.10 years; SD=10.56).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Financial toxicity across bladder cancer stages: systematic review
Economic impact of diagnostic testing
Share of bladder cancer costs attributable to surveillance
“Bladder cancer surveillance, including cystoscopy and recurrent imaging, contribute to more than half of the costs of the disease [17].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Another potential important target for decreasing variation and cost lies in risk-modified surveillance strategies after initial bladder tumor removal to reduce the cost associated with frequent cystoscopic and radiographic procedures.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Two scenarios where economic and comparative-effectiveness research is limited but would be most beneficial are (1) the management of NMIBC patients where excessive costs are due to vigilant surveillance strategies and (2) in patients with metastatic disease due to the enormous cost associated with late-stage and end-of-life care.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Medicare cost of surveillance testing during bladder-sparing therapy and after radical cystectomy
| Surveillance regimen | Cost | Range | CPT codes |
|---|---|---|---|
| Bladder-sparing therapy (CT urogram annually, cystoscopy and cytology every 3 months) | “3638 per year”View highlighted excerpt for this quote | “3384–7284”View highlighted excerpt for this quote | “74178, 88112, 52000”View highlighted excerpt for this quote |
| After radical cystectomy for NMIBC (annual CT urogram, cytology, laboratory tests, office visit) | “687 per year”View highlighted excerpt for this quote | “597–897”View highlighted excerpt for this quote | “74178, 85027, 80053, 82607, 88112”View highlighted excerpt for this quote |
Five-year cost of NMIBC surveillance by risk category
“A Markov model was constructed to determine the average 5-year costs for the surveillance of patients with NMIBC.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Cumulative costs of care over a 5-year period were $52,125 for low-risk, $146,250 for intermediate-risk, and $366,143 for high-risk NMIBC. The primary driver of cost was progression to muscle-invasive disease requiring definitive therapy, contributing to 81% and 92% of overall cost for intermediate- and high-risk disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Although protracted surveillance cystoscopy contributes to the expenditures associated with NMIBC, progression increases the overall cost of care across all three patient risk groups and most notably for intermediate- and high-risk disease patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cost-effectiveness of cystoscopic surveillance intensity in high-risk NMIBC
“We performed real-world clinical data-driven microsimulations of a hypothetical cohort of 100 000 patients diagnosed with HRNMIBC at age 70 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Compared to surveillance intensity de-escalation, higher-intensity regimens incurred an incremental cost of ≥$336 000 per incremental quality-adjusted life year gained, which well exceeded conventional willingness-to-pay thresholds, ≥$686 000 per additional MIBC progression prevented, and ≥$2.2 million per additional cancer-related mortality avoided.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Approaches to treatment
Current treatment options and standard of care
Radical cystectomy
Guideline recommendation: radical cystectomy as the standard option for BCG-unresponsive disease
Standard of care, morbidity, and deferral of surgery
“Standard treatment for patients with BCG-unresponsive NMIBC is radical cystectomy, which carries substantial morbidity and mortality; the incidence of complications is 35% to 40% and the 90-day mortality rate is 4.7%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Major guidelines recommend radical cystectomy (RC) with urinary diversion as the standard‐of‐care for BCG‐unresponsive NMIBC due to higher propensity for disease recurrence and progression” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cancer‐specific survival (CSS) is >80% after RC is performed for NMIBC” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, many patients defer RC due to concerns about perioperative morbidity and its impact on quality of life (QoL).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although radical cystectomy is the preferred treatment for BCG-unresponsive disease” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“surgery is associated with considerable morbidity and mortality risks, which are particularly germane for patients with this disease, who are often older and have comorbid conditions” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Upfront radical cystectomy compared with bladder-sparing therapy: multicenter retrospective cohort
“Among 578 patients, 28% underwent upfront RC and 72% received BST. The median (interquartile range) follow‐up was 50 (20–69) months. There were no statistically significant differences in metastasis‐free survival, cancer‐specific survival, or overall survival between treatment groups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“RC was performed in 31.7% in the BST group and nodal disease was found in 13% compared with 4% in upfront RC (P = 0.030).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no significant differences in MFS (HR 0.88, 95% CI 0.53–1.46; P = 0.62), CSS (HR 0.91, 95% CI 0.54–1.53; P = 0.73), or OS (HR 1.31, 95% CI 0.91–1.90; P = 0.15) between patients who received upfront RC compared to those receiving BST at time of diagnosis of BCG‐unresponsive NMIBC (Fig. 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although adverse oncological outcomes began to rise 12 months after diagnosis, the rate of dying from bladder cancer were similar at 14% in both the upfront RC and BST groups at 5 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The low rates of metastasis and death for patients who underwent BST are reassuring, but comparison with RC is impacted by selection bias.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Radical cystectomy compared with bladder-sparing therapy: prospective CISTO cohort, 12-month results
“Of 570 participants (mean age 71.4 years; 21% female), 371 selected BST and 199 selected RC. Physical function was significantly worse in the RC arm at 3 months; by 9 months, there was no difference between arms, and at 12 months, physical function did not differ (ATE, 0.9; 95% CI, –0.6 to 2.4; P = .22).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cancer-specific survival was 99% for BST versus 96% for RC (wRR, 0.99; 95% CI, 0.97 to 1.01). RC was associated with a higher risk of adverse events and serious adverse events, including a 90-day mortality rate of 2.5%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among participants who selected RC, 15 (8.0%) experienced prolonged hospitalization after their RC, 57 (30%) were readmitted within 90 days, and five (2.5%) died within 90 days” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Upstaging occurred among 22% of patients undergoing RC, reflective of the higher cancer severity in the RC arm and well-established understaging of bladder cancer with imaging and endoscopy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Timing of radical cystectomy after BCG failure
“Five-year overall and cancer specific survival was similar in groups 1 and 2 at 80% and 85%, respectively, at approximately equivalent followups. Median bladder retention was 1.7 years longer in group 2 (p <0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“On multivariate Cox regression analysis delayed cystectomy in group 2 did not convey a significant hazard for all cause mortality after cystectomy (HR 1.08, p = 0.808).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the historical cohort the 85 patients with documented T1 recurrence were initially treated with repeat transurethral resection and intravesical bacillus Calmette-Guerin.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At 5 years after T1 recurrence, the cumulative incidence of progression to T2 disease was 71% (95% CI 61%, 81%) and the cumulative incidence of death from disease was 48% (95% CI 39%, 60%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In this cohort 65 of the 129 patients with recurrent T1 underwent immediate radical cystectomy. At 5 years after T1 recurrence, the cumulative incidence of progression to muscle invasive disease was 28% (95% CI 20%, 38%) and the cumulative incidence of death from disease was 31% (95% CI 22%, 42%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Early complications of radical cystectomy: standardized reporting in 1,142 procedures
“Sixty-four percent (735/1142) of patients experienced a complication within 90 d of surgery.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, the highest grade of complication was grade 0 in 36% (n=407), grade 1-2 in 51% (n=582), and grade 3-5 in 13% (n=153). Gastrointestinal complications were most common (29%), followed by infectious complications (25%) and wound-related complications (15%). The 30-d mortality rate was 1.5%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Ninety-day mortality after radical cystectomy: muscle-invasive disease, National Cancer Database
“Among 7922 patients, 90-day mortality was 7.6% (8.0% for lower and 6.7% for higher volume hospitals).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The model predicted 25% of patients had a 90-day mortality risk higher than 10%, and observed 90-day mortality in this group was 14.0% (95% CI = 12.5% to 15.6%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Intravesical chemotherapy
Guideline description: intravesical chemotherapy and chemotherapy combinations
Guideline description: device-assisted chemotherapy
Approval status: valrubicin approved, other intravesical chemotherapy used off-label
“Other intravesical chemotherapies commonly used off-label include gemcitabine, mitomycin C, and the doublet of gemcitabine and docetaxel.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For over two decades, valrubicin was the only United States Food and Drug Administration (FDA) approved intravesical treatment for patients with BCG‐unresponsive carcinoma in situ (CIS) despite disease‐free rates of only 10% at 1 year following treatment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Other options include non‐FDA approved therapies such as sequential intravesical gemcitabine and docetaxel” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“which is supported by retrospective evidence only and no prospective clinical trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Valrubicin: labeled indication, dosing, and administration
Valrubicin: efficacy in BCG-refractory carcinoma in situ
Valrubicin: safety and the risk of delayed cystectomy
Sequential gemcitabine and docetaxel: multi-institution retrospective cohort after BCG
“Overall 276 patients (median age 73 years, median followup 22.9 months) received treatment. Nine patients were unable to tolerate a full induction course. One and 2-year recurrence-free survival rates were 60% and 46%, and high grade recurrence-free survival rates were 65% and 52%, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Forty-three patients (15.6%) went on to cystectomy (median 11.3 months from induction), of whom 11 (4.0%) had progression to muscle invasion.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Sequential gemcitabine and docetaxel: long-term single-institution follow-up after BCG failure
“Median follow-up was 49 months. Median age was 73 years, and 71% of the cohort had CIS containing disease. Thirty five percent of the cohort had BCG-unresponsive disease. Complete response at 3-month surveillance was 74% and median duration of response was 25 months. At 1, 2, and 5 years, HG-RFS was 60%, 50%, and 30%, respectively. HG-RFS was similar among BCG-unresponsive patients and the overall cohort.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Five-year PFS, CFS, CSS, and OS were 82%, 75%, 91%, and 64%, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Sequential gemcitabine and docetaxel compared with additional BCG in BCG-unresponsive disease
“Of 299 total patients, 204 underwent additional BCG treatment at the time of BCG unresponsiveness and 95 underwent gem/doce treatment. Rates of PFS (HR 2.6, 95% confidence interval [CI] 1.1-5.0, p = 0.03), CFS (HR 2.0, 95% CI 1.2-3.4, p = 0.01), and CSS (HR 3.7, 95% CI 1.1-12.3, p=0.03) were higher in patients receiving gem/doce. HGRFS, MFS, and OS were similar between both groups.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Sequential gemcitabine and docetaxel: prospective two-institution cohort in BCG-unresponsive disease
“Sixty-three patients were included. The median follow-up was 14 mo (interquartile range = 8-27). HGRFS rates at 3 and 12 mo were 88.8% (95% confidence interval [CI] = 81.3-97.0) and 68.1% (95% CI = 56.6-81.8), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Eight patients (12.7%) underwent radical cystectomy and six patients (9.5%) experienced disease progression. Twenty patients (31.7%) experienced mild irritative symptoms and no grade 3 or 4 adverse events were reported.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Gemcitabine alone compared with sequential gemcitabine and docetaxel: regimens and outcomes
“Patients received 2 g of gemcitabine in 100 mL of saline, instilled into the bladder via a catheter for a minimum of 60 minutes once weekly for 6 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients received 1 g of gemcitabine in 50 mL of saline, instilled via catheter for 60 to 90 minutes. The bladder was then drained, and 37.5 mg of docetaxel in 50 mL of saline was instilled via a catheter for 60 to 120 minutes. This treatment sequence was administered weekly for 6 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median HGRFS was similar between groups (gemcitabine: 22.6 months; Gem/Doce: 19.5 months [P=.25]). Among patients with BCG-unresponsive carcinoma in situ (n=49), median HGRFS was comparable (gemcitabine: 12.2 months; Gem/Doce: 7.6 months [P=.12]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Low-grade adverse events were common (gemcitabine: 63%; Gem/Doce: 55% [P=.19]), but grade ≥3 adverse events were rare (2.3% vs 2.4%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Sequential Gem/Doce also poses logistical barriers, including extended chair time, sequential instillation, staffing demands, and reimbursement issues, which may limit its adoption, especially in community settings.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Intravesical gene therapy
Guideline description: nadofaragene firadenovec
Nadofaragene firadenovec: labeled indication
Nadofaragene firadenovec: dosing and administration
Nadofaragene firadenovec: efficacy in the pivotal trial (label)
| Efficacy outcome measure (Study CS-003) | Adstiladrin (n=98) |
|---|---|
| Complete response rate | “51%” |
| 95% CI | “(41%, 61%)” |
| Median duration of response in months (range) | “9.7 (3, 52+)” |
| Duration of response ≥ 12 months | “46%” |
Nadofaragene firadenovec: phase 3 trial results by cohort
“55 (53·4%) of 103 patients with carcinoma in situ (with or without a high-grade Ta or T1 tumour) had a complete response within 3 months of the first dose and this response was maintained in 25 (45·5%) of 55 patients at 12 months. Micturition urgency was the most common grade 3–4 study drug-related adverse event (two [1%] of 157 patients, both grade 3), and there were no treatment-related deaths.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the high-grade Ta or T1 cohort, 35 of 48 patients (72·9%; 95% CI 58·2 to 84·7) were high-grade recurrence-free at month 3, and 21 patients (43·8%; 29·5 to 58·8) were recurrence-free at month 12.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Nadofaragene firadenovec: 5-year follow-up of the phase 3 trial
“Median follow-up was 50.8 months (interquartile range 39.1-60.0), with 27% receiving ≥ 5 instillations and 7.6% receiving treatment for ≥ 57 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Kaplan-Meier–estimated HGRF survival at 57 months was 13% (95% CI 6.9-21.5) and 33% (95% CI 19.5-46.6) in the CIS and Ta/T1 cohorts, respectively. Cystectomy-free survival at month 60 was 49% (95% CI 40.0-57.1): 43% (95% CI 32.2-53.7) in the CIS cohort and 59% (95% CI 43.1-71.4) in the Ta/T1 cohort. Overall survival at 60 months was 80% (71.0, 86.0): 76% (64.6-84.5) and 86% (70.9-93.5) in the CIS and Ta/T1 cohorts, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most adverse events were grades 1 or 2 (66%), with 3.8% of patients reporting grade 3 events and no patients experiencing grades 4 or 5 study-drug related adverse events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Nadofaragene firadenovec: FDA approval summary
“On December 16, 2022, the FDA approved the adenoviral vector-based gene therapy nadofaragene firadenovec-vncg (brand name Adstiladrin) for the treatment of adult patients with high-risk bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fifty subjects experienced CR 3 months after initial treatment (CR=51%; 95% CI: 40.7; 61.3%), of whom 46% remained in response for ≥12 months. The median DoR was 9.7 months (range: 3 to 52+).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Nadofaragene firadenovec: adverse reactions in the pivotal trial
Nadofaragene firadenovec: warnings on delayed cystectomy and disseminated adenovirus infection
Nadofaragene firadenovec: real-world outcomes at a multisite academic center
“Of 24 evaluable patients with carcinoma in situ with/without papillary disease, 79% had a CR at 3 months. The median response duration was not reached; 68% (13/19) of responders still had CRs with median follow-up of 9.3 months. Of 19 patients with papillary-only disease (median follow-up of 7.6 months), HGRFS at 3, 6, and 12 months was 68%, 53%, and 26%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common adverse events were grade 1–2 bladder spasms (61%) and failure to fully retain the instillation (33%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Detalimogene voraplasmid: investigational non-viral gene therapy, LEGEND pivotal Cohort 1
Detalimogene voraplasmid: LEGEND phase 2 dosing regimen
Interleukin-15 receptor agonists
FDA-approved indication and mechanism: nogapendekin alfa inbakicept-pmln with BCG
Dosage and administration with BCG
Expanded indication to papillary-only disease by extrapolation, October 2026
QUILT-3.032 Cohort A: design and population
QUILT-3.032 Cohort A: efficacy in the prescribing information
| Endpoint | Nogapendekin alfa inbakicept-pmln with TICE BCG |
|---|---|
| Participants | “n=77” |
| Complete response rate (95% CI) | “62% (51, 73)” |
| Duration of response, range in months | “0.0, 47.0+” |
| Duration of response ≥12 months, % (n) | “58% (28)” |
| Duration of response ≥24 months, % (n) | “40% (19)” |
| Basis of duration of response | “Based on 48 patients that achieved a complete response at any time” |
QUILT-3.032 Cohort A: long-term follow-up in 100 participants
“Participants received 400 mcg NAI in combination with 50 mg BCG through intravesical instillation weekly for 6 weeks, with optional reinduction if complete response (CR) was not achieved at month 3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The CR rate (n = 100) was 71% (95% CI 61.1-79.6) with a median duration of CR of 26.6 months (range 0.03-53.62).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This included 56 participants who responded to the initial induction treatment and 15 participants receiving reinduction treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The Kaplan-Meier estimated cystectomy-free rate in the 71 responders at 24 and 36 months was 90.3% (95% CI 79.7-95.6) and 84.2% (95% CI 69.6-92.1), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
QUILT-3.032 Cohort B: papillary-only disease
“NCT03022825 is an open-label, multicenter study of patients with BCG-unresponsive high-grade Ta/T1 papillary nonmuscle-invasive bladder cancer who received 400 μg NAI plus 50 mg BCG intravesically weekly for 6 consecutive weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary end point is disease-free survival (DFS) at 12 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At July 15, 2024, data cutoff, the DFS rates at 12, 24, and 36 months were 58.2% (95% CI: 46.6, 68.2), 52.1% (95% CI: 40.3, 62.7), and 38.2% (95% CI: 25.6, 50.6), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cystectomy avoidance rates at 12 and 36 months were 92.2% (95% CI: 83.4, 96.4) and 81.8% (95% CI: 68.1, 90.1), with median time to cystectomy not reached.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
European guideline summary of QUILT-3.032
FDA review: contribution of each component of the combination
“Cohort C (N-803 as a single agent) was closed early due to futility based on 10 patients; CRR was 20% [95% CI: 3, 56] with only 1 patient with a durable CR ≥ 6 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The CRR with BCG was 14% [95% CI: 2, 43], indicating that the response rate observed with the combination of N-803 and BCG did not appear to be due solely to the activity of BCG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“TICE BCG was the only strain studied in QUILT-3.032 and is currently the only approved BCG strain marketed in the U.S.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety in QUILT-3.032 Cohort A
Progression to muscle-invasive disease and delayed cystectomy
Intravesical drug-releasing systems
FDA-approved indication and mechanism: gemcitabine intravesical system
European guideline description of TAR-200
SunRISe-1 Cohort 2: design and population
SunRISe-1 Cohort 2: efficacy in the prescribing information
| Endpoint | Gemcitabine intravesical system |
|---|---|
| Participants | “N=83” |
| Complete response rate (95% CI) | “82% (72, 90)” |
| Duration of response, range in months | “0+, 44+” |
| Duration of response ≥12 months, % (n) | “51% (35)” |
| Basis of duration of response | “Based on patients (n=68) with a complete response at any time” |
SunRISe-1 Cohort 2: published complete response and duration of response
“The centrally confirmed CR rate in Cohort 2 was 82.4% (95% CI, 72.6 to 89.8), with 70 of 85 patients achieving CR” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After a median follow-up in responders of 20.2 months (range, 5-48), median DOR was 25.8 months (95% CI, 8.3 to not estimable” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among 70 responders, 37 (52.9%) had a DOR of ≥12 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
SunRISe-1 Cohort 4: papillary-only disease
“Fifty-two patients with BCG-unresponsive high-risk papillary disease–only NMIBC received TAR-200 monotherapy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The Cohort 4 primary end point was disease-free survival (DFS).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After a median follow-up of 12.8 months (range, 4-17), the median DFS was not estimable.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At 6, 9, and 12 months, DFS rates were 85.3% (95% CI, 71.6 to 92.7), 81.1% (95% CI, 66.7 to 89.7), and 70.2 (95% CI, 51.6 to 82.8), respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety in SunRISe-1 Cohort 2
Progression to muscle-invasive disease and MRI conditions
Randomized phase 3 trial in papillary-only disease: SunRISe-5
Immune checkpoint inhibitors
FDA-approved indication: pembrolizumab as a single agent
Recommended dosage in BCG-unresponsive high-risk NMIBC
KEYNOTE-057 Cohort A: design and population
KEYNOTE-057 Cohort A: efficacy in the prescribing information
| Endpoint | Pembrolizumab 200 mg every 3 weeks |
|---|---|
| Participants | “n=96” |
| Complete response rate (95% CI) | “41% (31, 51)” |
| Median duration of response, months (range) | “16.2 (0.0+, 30.4+)” |
| Duration of response ≥12 months, % (n) | “46% (18)” |
| Basis of duration of response | “Based on patients (n=39) that achieved a complete response” |
KEYNOTE-057 Cohort A: primary publication
“In cohort A of the trial, adults aged 18 years or older with histologically confirmed BCG-unresponsive carcinoma in situ of the bladder, with or without papillary tumours, with an Eastern Cooperative Oncology Group performance status of 0-2, and who were ineligible for or declined radical cystectomy were enrolled.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The primary endpoint was clinical complete response rate (absence of high-risk non-muscle-invasive bladder cancer or progressive disease), assessed by cystoscopy and urine cytology approximately 3 months after the first dose of study drug.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median follow-up was 36·4 months (IQR 32·0-40·7).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“39 (41%; 95% CI 30·7-51·1) of 96 patients with BCG-unresponsive carcinoma in situ of the bladder with or without papillary tumours had a complete response at 3 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Grade 3 or 4 treatment-related adverse events occurred in 13 (13%) patients; the most common were arthralgia (in two [2%] patients) and hyponatraemia (in three [3%] patients).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
KEYNOTE-057 Cohort B: papillary-only disease
“Cohort B eligible patients were aged 18 years and older, had an Eastern Cooperative Oncology Group performance status of 0-2, and had BCG-unresponsive high-risk non-muscle-invasive bladder cancer with papillary tumours (high-grade Ta or any-grade T1) without carcinoma in situ.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Primary endpoint was 12-month disease-free survival of high-risk non-muscle-invasive bladder cancer or progressive disease as assessed by cystoscopy, cytology, and central pathology and radiology review.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The 12-month disease-free survival was 43·5% (95% CI 34·9-51·9).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment-related adverse events occurred in 97 (73%) of 132 patients; 19 (14%) had a grade 3 or 4 treatment-related adverse event; the most common grade 3 or 4 treatment-related adverse events were colitis (in three [2%] patients) and diarrhoea (in two [2%]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Findings will need to be confirmed in a randomised controlled trial.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Safety in KEYNOTE-057
FDA advisory committee review of KEYNOTE-057
“In KEYNOTE-057, the CRR at first disease assessment was 41% (95% CI: 31%, 51%) and median DOR was 16.2 months; 46% of responders remaining in response for at least 1 year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The committee voted 9–4 in favor of a favorable benefit-risk profile for these patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Other checkpoint inhibitors: atezolizumab in SWOG S1605
Limitations of current therapies
Summary: limitations of cystectomy and of approved bladder-sparing therapies
The EAU guideline states that radical cystectomy is the standard and preferred option for BCG-unresponsive disease and that other treatments must be considered oncologically inferior; it recommends bladder-preserving strategies, preferably within clinical trials, for patients who are not candidates for cystectomy or who decline it. Up to 80% of patients decline or are ineligible for cystectomy. Reported risks of the procedure include morbidity of 50% to 70% and 90-day mortality of approximately 5% (up to 15% in elderly patients), and a manufacturer-funded cost model states that up to one-quarter of patients die and approximately 70% to 80% experience complications within the first year after surgery.
Pembrolizumab, nogapendekin alfa inbakicept-pmln with BCG, and the gemcitabine intravesical system were each approved on the basis of single-arm trials. Their labeled complete response rates were 41% (96 participants), 62% (77 participants), and 82% (83 participants), and no randomized trial compares these agents with each other or with cystectomy. FDA draft guidance states that a randomized controlled trial is preferable and can provide stronger evidence of effectiveness, that time-to-event endpoints are uninterpretable in a single-arm trial, and that a single-arm study cannot assess the contribution of each drug in a combination. For papillary-only disease resected at or before trial entry, the FDA recommends a randomized controlled trial with a time-to-event endpoint. In October 2026, the FDA extended the nogapendekin alfa inbakicept-pmln indication to papillary-only disease by extrapolation from efficacy in disease containing CIS. Labeling for pembrolizumab and the gemcitabine intravesical system is limited to disease with CIS, and pembrolizumab is further limited to patients ineligible for or electing not to undergo cystectomy. Of 31 BCG-unresponsive trials registered on ClinicalTrials.gov, 15 (48%) had enrollment criteria fully consistent with the FDA definition, which the authors state hinders comparisons across agents.
In a meta-analysis of bladder-sparing trials after BCG failure cited by the EAU guideline, pooled 12-month response rates were 24% for trials with more than 2 prior BCG courses and 36% for those with more than 1, and initial response did not predict durable response. Among responders, 46% (pembrolizumab), 58% (nogapendekin alfa inbakicept-pmln with BCG), and 51% (gemcitabine intravesical system) had a duration of response of at least 12 months in the labels. In QUILT-3.032 Cohort A, complete response rates at the 12-, 24-, and 36-month assessments were 47%, 30%, and 16% of 100 participants; in SunRISe-1 Cohort 2, the complete response rate 12 months after treatment initiation was 45.9%. The QUILT-3.032 median duration of response was considered an unreliable estimate because of the limited sample size, small number of events, and substantial censoring. Progression to muscle-invasive disease occurred in 10% (8 participants) in QUILT-3.032 and 8% (7 of 83 evaluable participants) in SunRISe-1 Cohort 2, and each label warns that delaying cystectomy can lead to muscle-invasive or metastatic disease.
Nogapendekin alfa inbakicept-pmln is given with BCG, and TICE BCG is the only approved BCG strain marketed in the U.S. Merck, its sole U.S. manufacturer since 2012, allocates supply to wholesalers and distributors by historical purchasing patterns; in its 2026 letter to health care professionals it reported delays to full startup of a new facility and stated that it will provide an update on timing in the first quarter of 2027. In Medicare claims, BCG use for initial induction therapy decreased from 38.9% before the shortage to 33.0% during it.
Guideline position on radical cystectomy and bladder-sparing therapy
Cystectomy refusal, ineligibility, and perioperative risk
“The current standard of care for BCG-unresponsive high-risk NMIBC is radical cystectomy,” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“which is a life-changing surgery associated with considerable morbidity (50%-70%) and significant impact on quality of life.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Radical cystectomy is also associated with substantial 90-day mortality risk (approximately 5%), particularly in elderly patients (≤15%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Therefore, many patients are unable or unwilling to undergo this procedure, and real-world rates of radical cystectomy for NMIBC are low (<20%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Limitations of approved bladder-sparing therapies stated by trial investigators
“However, these treatments are associated with limited complete response (CR) rates and response durability, systemic or immune-related toxicities, frequent urethral catheterizations, reliance on BCG as combination therapy, and limited physician adoption.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Single-arm trial evidence and FDA trial design recommendations
“An RCT is preferrable and can” (opens the source at this quote in a new tab)
“single-arm study.” (opens the source at this quote in a new tab)
“recurrence-free survival.” (opens the source at this quote in a new tab)
“However, the review of QUILT-3.032 highlighted several challenges in interpreting single-arm data in this disease setting.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One key consideration is that both the primary endpoint of CRR and the key secondary endpoint of DoR may be impacted by heterogeneity across investigators in disease assessment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, a randomized trial with a time-to-event endpoint would be required to demonstrate benefit in patients with papillary-only disease due to the lack of an available response endpoint for resected tumors and variability in the natural history of resected papillary disease, which challenges the interpretation of uncontrolled time-to-event endpoints.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A limitation was the noncomparative cohort design.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The duration of follow-up in the present analysis (median, 20.2 months in Cohort 2 responders) limits the ability to draw firm conclusions regarding long-term efficacy and safety of TAR-200 treatment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Heterogeneity of trial enrollment criteria
“Of 31 trials, 15 (48%) had inclusion/exclusion criteria that were fully consistent with (inclusive of patients that met) the BCG unresponsive bladder cancer definition.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The most common disease specific exclusion for patients with BCG unresponsive bladder cancer was a requirement for stage Tis (carcinoma in situ, CIS), which pertained to 7 (23%) of trials.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For bladder cancer treating physicians and regulatory bodies, this also hinders comparisons across agents.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Durability of complete response
“At the 12-, 24-, and 36-month response assessments, CR rates were 47% (47 of 100; 95% CI 36.9%-57.2%), 30% (30 of 100; 95% CI 21.2%-40.0%), and 16% (16 of 100; 95% CI 9.4%-24.7%), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At 3, 6, and 12 months after treatment initiation, CR rates were 78.8% (95% CI, 68.6 to 86.9), 58.8% (95% CI, 47.6 to 69.4), and 45.9% (95% CI, 35.0 to 57.0), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For context, among patients treated with pembrolizumab, nadofaragene firadenovec, or NAI plus BCG, 46%-58% had a DOR of ≥12 months, with CIs overlapping.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, given the limited sample size, small number of events, and substantial censoring from approximately 12–15 months, the median DOR in QUILT-3.032 was considered an unreliable estimate.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A post-marketing commitment to better characterize the response duration and risk for progression in all patients was agreed upon with the Applicant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
BCG supply constraints
“Among eligible patients, BCG utilization rates for initial induction therapy decreased 5.9%, from 38.9% (1030 of 2648 patients) in the pre-shortage period, to 33.0% (1756 of 5323 patients) in the shortage period” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Place in treatment, anticipated use, and care setting
Summary: anticipated place in treatment and care setting
Radical cystectomy is the guideline standard for BCG-unresponsive disease; the EAU 2026 guideline recommends offering it and recommends bladder preservation strategies, preferably within clinical trials, for patients who are not candidates for cystectomy or who decline it. BOND-003 enrolled participants who were medically unfit for cystectomy or who refused it, and the FDA draft guidance states that patients with BCG-unresponsive NMIBC “are unlikely to benefit from further therapy with BCG”. CG Oncology states that only approximately 6% of patients with NMIBC elect cystectomy, and another publication reports real-world rates of radical cystectomy for NMIBC below 20%.
The anticipated first use is in BCG-unresponsive high-risk NMIBC with carcinoma in situ, with or without papillary tumors. In its PIVOT-006 topline release, CG Oncology stated that, based on FDA feedback, the initial BLA will be broadened to include both carcinoma in situ and high-grade papillary-only disease, with completion anticipated in March 2027. Cretostimogene would enter a setting in which the FDA has approved pembrolizumab, nadofaragene firadenovec, nogapendekin alfa inbakicept-pmln with BCG, and TAR-200 for high-risk, BCG-unresponsive NMIBC with CIS ± Ta/T1.
The expected care setting is the urology office. BOND-003 Cohort C was run at 41 community and academic centres. Cretostimogene is instilled through a soft catheter without anesthesia or operating room time, and the company states that a medical assistant or nurse can prepare and administer it. The product is handled under biosafety level 2 precautions, described as “BSL-2 like BCG”, with protective equipment during preparation and administration. CG Oncology describes a field organization directed at community and academic urology networks.
Guideline position of radical cystectomy and bladder preservation
Population that declines or is unfit for cystectomy
Company positioning as a bladder-sparing therapy after BCG
Anticipated initial indication including papillary-only disease
Care setting: in-office intravesical instillation without anesthesia
“BOND-003 Cohort C is a single-arm, international, phase 3 study done in 41 centres (community practices and academic centres) located in North America, Asia, and Australia.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Care setting: biosafety handling in the urology office
Prescriber network targeted for launch
Heterogeneity of treatment effect
BOND-003 Cohort C: complete response in second-line and chemotherapy-pretreated subgroups
BOND-003 Cohort C: subgroup consistency and response after re-induction
BOND-003 Cohort C: cystectomy-free survival across subgroups
Comparator trial: TAR-200 by presence of papillary disease and T stage
“Subgroup analyses showed consistently high CR rates across all clinically relevant subgroups, including patients with and without concurrent papillary disease (82.1% and 82.5%, respectively; Data Supplement, Fig S2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Twelve-month DFS rates were consistent in patients with high-grade Ta and T1 disease (70.0% [95% CI, 44.8 to 85.4] and 72.2% [95% CI, 44.8 to 87.6], respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Comparator trials: carcinoma in situ cohorts and papillary-only cohorts
Systematic reviews: predictors of response after BCG failure
Regulatory guidance on stratification by tumor pattern
Variable enrollment criteria across BCG-unresponsive trials
“Of 31 trials, 15 (48%) had inclusion/exclusion criteria that were fully consistent with (inclusive of patients that met) the BCG unresponsive bladder cancer definition.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The most common disease specific exclusion for patients with BCG unresponsive bladder cancer was a requirement for stage Tis (carcinoma in situ, CIS), which pertained to 7 (23%) of trials.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For bladder cancer treating physicians and regulatory bodies, this also hinders comparisons across agents.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Care management intervention strategies
Nursing considerations before and during instillation
Patient education and follow-up after instillation
Response surveillance schedule in BOND-003
Re-induction for persistent disease at 3 months
“Patients received intravesical cretostimogene (1 × 1012 viral particles per 0·8 mL per week) as 6-week induction followed by maintenance; re-induction was permitted for persistent disease at 3 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Treatment adherence and resolution of treatment-related adverse events
Cystectomy decisions with comparator bladder-sparing therapies
Multidisciplinary tumour board review
Other product development or post-marketing obligations required by the FDA
Not applicable.
Ongoing post-approval monitoring
Not applicable.
Expected outcomes of therapy
Complete response at any time in BOND-003 Cohort C
“As of June 23, 2025, after a median follow-up of 25·8 months (IQR 22·1-33·1), complete response at any time was observed in 83 (75% [95% CI 66·3-83·2]) of 110 patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Cretostimogene showed clinically meaningful anti-tumour response, with an adverse event profile characterised predominantly by low-grade, transient events.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote